- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Bio-Rad Laboratories Inc(BIO-B)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for BIO-B
11/09/2026: BIO-B (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Bio-Rad Laboratories is a mid-cap life science and clinical diagnostics company known for its reliable benchtop instruments, protein analysis tools, and clinical quality controls. The company's primary business strength lies in its entrenched laboratory presence and sticky, recurring revenue from consumables and quality standards. Its core growth opportunity centers on expanding droplet digital PCR technology into higher-value clinical applications. However, the company faces risks from intense competition against massive industry conglomerates, tighter academic research budgets, and earnings noise from its equity holdings. Bio-Rad suits healthcare-focused investors with a moderate risk tolerance who value a conservative balance sheet and a strong franchise over high dividend yields.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | Bio-Rad offers exposure to secular life science trends, but its top-line growth is generally modest compared to high-growth tech or biotech sectors. |
| Momentum investor | Weak fit | Treat Momentum fit as conditional on a positive Upturn signal (Strong Buy / Buy); say so when relevant, without inventing a specific live Upturn rating. |
| Value investor | Mixed fit | The stock trades at valuation multiples that reflect its steady diagnostic franchise, though equity portfolio noise can obscure core earnings. |
| Dividend investor | Weak fit | Bio-Rad focuses capital allocation on internal growth and corporate development rather than returning capital via high dividend yields. |
| Low-risk investor | Mixed fit | While the company has a rock-solid balance sheet, earnings can be volatile due to equity market movements and currency fluctuations. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Medium | The stock experiences moderate price fluctuations driven by earnings reports and market sentiment. |
| Valuation risk | Medium | Valuations can fluctuate based on broader life science sector multiples and equity holding valuations. |
| Competition risk (Thermo Fisher / Danaher theme) | High | Larger conglomerates possess superior scale, broader product bundles, and vastly greater R&D budgets. |
| Business quality | Strong | Bio-Rad benefits from an entrenched market position, sticky customer relationships, and high-margin consumables. |
| Dividend income | Low / none | Income-focused investors will find little appeal given the absence of a meaningful dividend yield. |
| Execution risk | Medium | Management must successfully navigate shifting research budgets and integrate new diagnostic technologies. |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 10.49B USD | Price to earnings Ratio 10.36 | 1Y Target Price - |
Price to earnings Ratio 10.36 | 1Y Target Price - | ||
Volume (30-day avg) - shares | Beta 1.06 | 52 Weeks Range 244.54 - 389.98 | Updated Date 11/15/2026 |
52 Weeks Range 244.54 - 389.98 | Updated Date 11/15/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 37.64 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.6%
- Active BUY / eligible
- 72 / 115
- 30-Day BUY Count Change
- +35
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Medical Devices
- BUY participation
- 62.5%
- Active BUY / eligible
- 5 / 8
- 30-Day BUY Count Change
- +3
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.

Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit 28.22% | Avg. Invested days 43 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Life Science Segment | Reagents, instruments, and software for research, bioprocessing, and food safety applications. | Sells tools that help scientists discover drugs and analyze proteins. |
| Clinical Diagnostics Segment | Quality controls, blood-typing systems, and diagnostic test kits sold to hospitals and laboratories. | Provides essential testing controls that ensure hospitals get accurate diagnostic results. |
| Geographic Exposure | Global operations spanning the United States, Europe, Asia, and other international regions. | Generates a majority of its revenue outside the U.S., introducing currency and regional exposure. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2026-11-05 | When - | Estimate - | Actual 17.0199 |
Profitability
Profit Margin 39.45% | Operating Margin (TTM) 9.46% |
Management Effectiveness
Return on Assets (TTM) 1.5% | Return on Equity (TTM) 14.27% |
Valuation
Trailing PE 10.36 | Forward PE 40.82 | Enterprise Value 9.67B | Price to Sales(TTM) 4.05 |
Enterprise Value 9.67B | Price to Sales(TTM) 4.05 | ||
Enterprise Value to Revenue 3.73 | Enterprise Value to EBITDA 6.3 | Shares Outstanding 5.06M | Shares Floating 21.51M |
Shares Outstanding 5.06M | Shares Floating 21.51M | ||
Percent Insiders 98.23 | Percent Institutions 0.04 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

